Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats previously untreated Stage III or IV cHL. Sold as Adcetris. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Brentuximab Vedotin (sold as Adcetris), first approved Aug 19, 2011, with 8 new uses approved and 0 published complete response letters.
First approved: Aug 19, 2011
Applications: 2
New uses approved: 8
Complete response letters: 0
Medicare spending, 2025: $198M
Orphan exclusivity until: Nov 10, 2029
First approved in the EU: Oct 25, 2012
First approved in Japan: Jan 17, 2014
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 29 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
AdcetrisA drug with a new indication and a new dosage for the treatment of relapsed or refractory CD30- positive cutaneous T-cell lymphoma. · Takeda Pharmaceutical Company Limited · Nov 24, 2023
AdcetrisA drug with a new additional pediatric dosage indicated for the treatment of CD30-positive Hodgkin's lymphoma. · Takeda Pharmaceutical Company Limited · May 26, 2022
Adcetris1) A drug with a new indication and a new dosage for the treatment of CD30-positive peripheral T-cell lymphoma. · Takeda Pharmaceutical Company Limited · Dec 20, 2019 · Review report
AdcetrisA drug with a new indication and a new dosage for the treatment of CD30-positive Hodgkin’s lymphoma [Orphan drug] · Takeda Pharmaceutical Company Limited · Sep 21, 2018 · Review report
Adcetris, new ingredientA drug with a new active ingredient indicated for the treatment of relapsed or refractory CD30- positive Hodgkin’s lymphoma and anaplastic large- cell lymphoma. · Takeda Pharmaceutical Company Limited · Jan 17, 2014 · Review report
Clinical Trials
58 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
